 Proto-Oncogene Proteins c-met
"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations of the gene for PROTO-ONCOGENE PROTEINS C-MET are associated with papillary renal carcinoma and other neoplasia.
| Descriptor ID |
D019859
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.075 D12.776.543.750.060.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
|
| Concept/Terms |
Proto-Oncogene Proteins c-met- Proto-Oncogene Proteins c-met
- Proto Oncogene Proteins c met
- Hepatocyte Growth Factor Receptor
- HGF Receptor
- Scatter Factor Receptor
- Receptor, Hepatocyte Growth Factor
- Receptor, HGF
- Receptor, Scatter Factor
- c-met Proteins
- c met Proteins
- met Proto-Oncogene Proteins
- Proto-Oncogene Proteins, met
- met Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2002 | 2 | 0 | 2 | | 2003 | 3 | 2 | 5 | | 2004 | 2 | 0 | 2 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 11 | 2 | 13 | | 2008 | 3 | 3 | 6 | | 2009 | 7 | 3 | 10 | | 2010 | 7 | 2 | 9 | | 2011 | 8 | 2 | 10 | | 2012 | 2 | 0 | 2 | | 2013 | 6 | 1 | 7 | | 2014 | 6 | 0 | 6 | | 2015 | 2 | 2 | 4 | | 2016 | 4 | 3 | 7 | | 2017 | 3 | 3 | 6 | | 2018 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.
-
Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926.
-
Saintigny P, William WN, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
-
Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018 03 20; 36(9):911-919.
-
Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 11; 18(11):1467-1482.
-
Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
-
Maron SB, Catenacci DVT. Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematol Oncol Clin North Am. 2017 06; 31(3):511-527.
-
Maron SB, Catenacci DV. Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am. 2017 04; 26(2):293-312.
-
Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
-
Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
-
Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer. 2017 05 15; 123(6):1061-1070.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|